Brokers Offer Predictions for OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in a report issued on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($2.12) per share for the year. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01).

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. lowered their price target on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Oppenheimer restated an “outperform” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Olema Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $27.00.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $9.17 on Friday. The firm has a fifty day moving average price of $12.00 and a two-hundred day moving average price of $11.96. Olema Pharmaceuticals has a fifty-two week low of $8.51 and a fifty-two week high of $17.10. The company has a market cap of $525.42 million, a PE ratio of -4.19 and a beta of 2.02.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Swiss National Bank boosted its stake in Olema Pharmaceuticals by 8.8% in the 1st quarter. Swiss National Bank now owns 70,300 shares of the company’s stock valued at $796,000 after buying an additional 5,700 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Olema Pharmaceuticals in the 1st quarter valued at $176,000. Entropy Technologies LP bought a new stake in shares of Olema Pharmaceuticals in the 1st quarter worth about $161,000. EntryPoint Capital LLC increased its position in shares of Olema Pharmaceuticals by 949.9% during the 1st quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock worth $164,000 after purchasing an additional 13,146 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Olema Pharmaceuticals by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after purchasing an additional 1,486 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.